Compare Vanguard Mega Cap Growth ETF (MGK) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs 10X Genomics Inc — how do they compare? Vanguard Mega Cap Growth ETF trades at $94.42 (market cap $33.70B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: Vanguard Mega Cap Growth ETF is far larger — about 3.3× 10X Genomics Inc's market cap, and Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Mega Cap Growth ETF for 45 Days and 10X Genomics Inc for 91 Days on average.
| MGK | TXG | |
|---|---|---|
Market Cap | $33.70B | $10.07B |
Volume | 1,362,010 | 5,657,286 |
Sector | Broad Market / Factor | Health |
52-Week High | $95.11 | $97.74 |
52-Week Low | $70.70 | $11.48 |
Typical Hold Time | 45 Days | 91 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK, the Vanguard Morningstar Mega Cap Growth ETF, trades at $94.42, down 0.53% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides exposure to large-cap U.S. growth stocks like Nvidia and Apple, with a low expense ratio of 0.05% (Vanguard, 2026-07-18). Recent news highlights its strong five-year returns and suitability for long-term growth investors.
The outlook for MGK is positive, driven by its concentrated mega-cap growth holdings and cost efficiency, though risks include tech sector volatility and market concentration. Analyst sentiment is favorable, emphasizing its role in growth portfolios for investors seeking higher returns with manageable risk.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
